Some items on our site have recently moved. Visit our News Hub for selected articles, special reports, podcasts and other resources.
AbbVie, Allergan well-positioned for unconditional clearance in Brazil
22 Oct 2019 12:41 pm by Ana Paula Candil
AbbVie’s $63 million merger with Allergan is well-positioned for unconditional antitrust clearance in Brazil, MLex has learned.
Approval by the Administrative Council for Economic Defense, or CADE, is expected to be announced soon.
AbbVie and Allergan submitted merger paperwork on Aug. 22, but amended their notification form, pushing the review deadline to Nov. 14.
AbbVie and Allergan are listed on the New York Stock Exchange.
Related Articles
-
Nvidia's notification of its $40 billion Arm buyout to the EU merger authority is imminent -
NAB’s plans to acquire Citigroup’s Australian consumer business could create the country’s second-largest credit card provider. -
Aon's decision was also a victory for antitrust enforcement in the tradition of recent decades.